PriceTargets.com logo

Novus Therapeutics - NVUS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.27 As of 12/24/2024 01:00 AM ET
▲ +0.08 (1.91%)
Get New Novus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVUS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Novus Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.27.

This chart shows the closing price for NVUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Novus Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$43.00
6/2/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$10.80
5/11/2020Ascendiant Capital MarketsReiterated RatingBuy ➝ Market Perform$58.50
4/6/2020LADENBURG THALM/SH SHReiterated RatingBuy$45.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Novus Therapeutics logo
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Read More

Today's Range

Now: $4.27
Low: $4.03
High: $4.31

50 Day Range

MA: $13.23
Low: $9.85
High: $16.50

52 Week Range

Now: $4.27
Low: $4.50
High: $27.32

Volume

262,279 shs

Average Volume

78,851 shs

Market Capitalization

$6.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Novus Therapeutics?

The following Wall Street analysts have issued reports on Novus Therapeutics in the last year:
View the latest analyst ratings for NVUS.

What is the current price target for Novus Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Novus Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Novus Therapeutics in the next year.
View the latest price targets for NVUS.

What is the current consensus analyst rating for Novus Therapeutics?

Novus Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NVUS.

What other companies compete with Novus Therapeutics?

Other companies that are similar to Novus Therapeutics include Hookipa Pharma, AEON Biopharma, Chemomab Therapeutics, Cadrenal Therapeutics and BriaCell Therapeutics. Learn More about companies similar to Novus Therapeutics.

How do I contact Novus Therapeutics' investor relations team?

Novus Therapeutics' physical mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The biopharmaceutical company's listed phone number is 949-238-8090 and its investor relations email address is [email protected]. The official website for Novus Therapeutics is novustherapeutics.com. Learn More about contacing Novus Therapeutics investor relations.